Amerikanische Gesellschaft für Hirudotherapie

Unveiling salivary gland-specific gene expression of Piezo1 and Neuroendocrine in the leech Helobdella austinensis

Research article published in Developmental and comparative immunology (2025)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Preclinical (animal)Speichel-PharmakologiePyo IH et al. · Developmental and comparative immunology, 2025

Abstract

Mechanotransduction is a critical biological phenomenon in living organisms, with Piezo1 being one of the key mechanotransduction ion channel genes. Piezo1 is widely expressed across various tissues and organs, playing critical roles in numerous biological processes, including innate and adaptive immune activation. While most studies on Neuroendocrine and Piezo functions have focused on vertebrates and higher invertebrates (e.g., Drosophila), however research in lophotrochozoan animal models remains scarce. To address this gap, we utilized Helobdella austinensis (phylum: Annelida) to investigate the putative function of Piezo1 and uncovered evidence related to the neuroendocrine system through spatiotemporal characterization. Our findings represent the developmental contribution of Piezo1 from early to late embryonic stages by demonstrating its expression in a lophotrochozoan. Intriguingly, the expression of Hau-Piezo1 was specifically detected in salivary gland-related precursors and tissues during development. Additionally, Neuroendocrine expression was observed in a lophotrochozoan, suggesting the correlation between neuronal stimulation and immune cells along the salivary glands of leeches. Furthermore, the downregulation of Hau-Piezo1 following bacterial challenge suggests that Piezo1 plays a role in regulating inflammatory responses. Taken together, we characterized the spatiotemporal expression pattern of Hau-Piezo1 in leeches and demonstrated its conserved and diversified functions based on its phylogenetic relationship with other homologs. These results suggest that Piezo1 may serve as a salivary gland marker in leeches and provide evidence for the presence of immune cells along the salivary glands in lophotrochozoans.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsAnimalsSalivary GlandsIon ChannelsLeechesMechanotransduction, CellularNeurosecretory SystemsPhylogenyGene Expression Regulation, Developmental

Zusammenfassung

Unveiling salivary gland-specific gene expression of Piezo1 and Neuroendocrine in the leech Helobdella austinensis.

Warum dies für die Hirudotherapie relevant ist

This study examined the spatiotemporal expression of the mechanotransduction ion channel gene Piezo1 and neuroendocrine markers in the leech Helobdella austinensis. The researchers found that Hau-Piezo1 was specifically detected in salivary gland-related precursors and tissues during development, and its downregulation following bacterial challenge suggests a role in regulating inflammatory responses. For ASH, this is notable because it characterizes potential salivary gland markers in leeches and provides evidence for immune cells along the salivary glands, contributing to basic biological understanding of leech salivary biology. However, this is a developmental biology study in a non-medicinal leech species with no direct therapeutic or clinical data for hirudotherapy.

Zitation

Unveiling salivary gland-specific gene expression of Piezo1 and Neuroendocrine in the leech Helobdella austinensis

Pyo IH et al. · Developmental and comparative immunology, 2025

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.